Noticias y vídeos - MEDIWOUND

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden, July 15, 2024 GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in...

$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023 Conference c all b egins t oday at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on...

Paper published in the November 2022 issue of Podiatry Management (Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the publication of a paper, “ Introducing Bromelain-Based Enzymatic Debridement ” in the journal Podiatry Management. The paper...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD PR Newswire NEW YORK, July 18, 2021 NEW YORK , July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether MediWound and certain of its officers and/or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD PR Newswire NEW YORK, June 29, 2021 NEW YORK , June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether MediWound and certain of its officers and/or...

...

NEW YORK, NY / ACCESSWIRE / May 8, 2017 / MediWound Ltd. (NASDAQ: MDWD ) will be discussing their earnings results in their Q1 Earnings Call to be held May 8, 2017 at 8:30 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/22162 . Replay Information The replay will be available online at https://www.investornetwork.com/company/22162 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique investors...

YAVNE, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces final positive results from the Company’s second Phase 2 clinical trial evaluating EscharEx ® for debridement of dead or damaged tissue in chronic and other hard-to-heal wounds, which includes data from the follow-up period of six months from last treatment or three months...

YAVNE, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the United States Patent and Trademark Office (USPTO) has issued patent Number 9,511,126 with claims related to the Company’s proprietary injectable bromelain solution, MWPC003, for enzymatic treatment of connective tissue diseases. The new patent, titled...

YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid ® in the management of burns in mass casualty incidents was selected as “Best Poster” at the International Disaster and Military Medicine (DiMiMED) 4 th Annual Conference, held November 15-16 in Dusseldorf, Germany....

YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and nine months ended September 30, 2016. Highlights of the third quarter of 2016 include: Third quarter 2016 Revenue of $518,000 compared with $102,000 in the prior year’s third quarter, underscoring the Company’s progress growing NexoBrid...

YAVNE, Israel, Nov. 04, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and nine months ended September 30, 2016, at 7:00 a.m. Eastern time on November 14, 2016. Following the release, MediWound's management will host a conference call for the investment community beginning at...

YAVNE, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Credit Suisse 25th Annual Healthcare Conference taking place from November 6-8, 2016 in Scottsdale, Arizona. Gal Cohen, President and Chief Executive Officer, will deliver MediWound’s presentation on Monday, November 7th at...